Trial Profile
Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Lamivudine/abacavir; Nevirapine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SWAD
- 26 Jul 2017 Results (n=43) of PK substudy presented at the 9th International AIDS Society Conference on HIV Science
- 19 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.